上場企業の株式を5%以上取得した投資家は、Schedule 13D（積極的・支配的意図、多くはアクティビスト投資家）または13G（受動的投資）で開示しなければなりません——大株主の動向を最も早く知らせるシグナルです。
報告件数 (30日間)
488
対象企業数
345
意図表明あり
204
ランキング対象件数
61
データ更新日: 2026-09-18
| ティッカー | 企業名 | 報告件数 | 最新の意図表明 | 最終報告日 |
|---|---|---|---|---|
| EMPD | Empery Digital Inc. | 4 | Item 4 is hereby amended to add the following: On September 4, 2026, ATG Fund delivered a letter to the Issuer withdrawing its nominations of Arati Batta, Ronald H. Davies, Christopher E. Novak, Evan Ratner and Heather A. Powers for election to the Board at the Annual Meeting. Also on September 4, 2026, the Reporting Persons filed a definitive proxy statement with the Securities and Exchange Commission in connection with their solicitation of proxies for election of Gabriel D. Gliksberg, James C. Elbaor, Meredith S. Kirshenbaum and Aaron T. Morris to the Board at the Annual Meeting. | 2026-09-08 |
| VBIO | Valion Bio, Inc. | 4 | This Item 4 is not being amended by this Amendment No. 7. | 2026-09-04 |
| HZO | MARINEMAX INC | 3 | Item 4 of the Schedule 13D is hereby amended and supplemented to include the following: The transactions described in this Amendment No. 4 were undertaken solely to effect an internal reorganization of the PPF group of companies. Such transactions did not involve any change in the ultimate beneficial ownership of, or the ultimate voting or dispositive power over, the shares of Common Stock reported herein, and were not undertaken with any purpose of, or with the effect of, changing or influencing control of the Issuer. Other than as described herein, the Reporting Persons do not have any current plans or proposals which relate to or would result in any of the actions described in subparagraphs (a) through (j) above. | 2026-09-08 |
| GAP | The Gap, Inc. | 3 | This Statement is filed on behalf of the Reporting Person to update the beneficial ownership information from that reported in the Schedule 13D. The Reporting Person reviews their investments in the Issuer on a continuing basis and may, at any time, consistent with the obligations of the Reporting Person under the federal securities laws, determine to increase or decrease their respective ownership of shares of the Issuer's Common Stock through purchases or sales of such Common Stock of the Issuer in the open market, in privately negotiated transactions or by gift or other transfers as circumstances dictate. From time to time, the Reporting Person has transferred shares to various entities controlled by him, disposed of certain shares to third parties by gift and sold shares of Issuer Common Stock in the open market and in privately negotiated transactions, and the Reporting Person may do so in the future. The review of his investment in the Issuer by the Reporting Person will depend on various factors, including the Issuer's business prospects, other developments concerning the Issuer, alternative investment opportunities, general economic conditions, money and stock market conditions, and any other facts and circumstances which may become known to the Reporting Person regarding his investment in the Issuer. At the time of filing this Statement, the Reporting Person has no plans to sell or to purchase additional shares of Common Stock of the Issuer in the open market or in privately negotiated transactions but may engage in such transactions in the future. At the time of the filing of this Statement, except as disclosed herein, the Reporting Person has no present plans or proposals in his capacity as a stockholder which relate to or would result in (i) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer, (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (iii) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries, (iv) any change in the Board of Directors or management of the Issuer or any of its subsidiaries, (v) any material change in the present capitalization or dividend policy of the Issuer, (vi) any other material change in the Issuer's business or corporate structure; (vii) changes in the Issuer's charter or bylaws or other actions which may impede the acquisition of control of the Issuer by any person, (viii) causing a class of securities of the Issuer to be delisted from a national securities exchange or cease to be quoted in an inter-dealer quotation system of a registered national securities association, (ix) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (x) any action similar to any of those described above. However, because the Reporting Person is a member of the Board of Directors of the Issuer, he may, from time to time, be involved in discussions which relate to one or more of the matters described in this Item 4. The Reporting Person disclaims any obligation to report on any plans or proposals with respect to the matters described in this Item 4 that develop or occur as a result of his role as a director of the Issuer and participation in decisions regarding the Issuer's actions. | 2026-09-04 |
| MEOH | Methanex Corporation | 3 | The Reporting Person acquired the Common Stock to which this Schedule 13D relates for investment purposes in the ordinary course of business. The Reporting Person acquired the Common Stock because they believed that the Common Stock reported herein, when purchased, were undervalued and represented an attractive investment opportunity. The Reporting Person and their representatives have, from time to time, engaged in, and expect to continue to engage in, discussions with members of management and the board of directors of the Issuer (the "Board"), other current or prospective shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit and other third parties regarding a variety of matters relating to the Issuer, which may include, among other things, the Issuer's business, management, capital structure and allocation, environmental, social and governance matters, Board composition and strategic alternatives and direction, and may take other steps seeking to bring about changes to increase shareholder value as well as pursue other plans or proposals that relate to or could result in any of the matters set forth in clauses (a)-(j) of Item 4 of Schedule 13D. The Reporting Person intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the outcome of any discussions referenced above, the Issuer's financial position, results and strategic direction, actions taken by the Issuer's management and the Board, price levels of the Common Stock, other investment opportunities available to the Reporting Person, conditions in the securities market and general economic and industry conditions, the Reporting Person reserve the right in the future to take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, exchanging information with the Issuer pursuant to appropriate confidentiality or similar agreements; proposing changes in the Issuer's operations, governance or capitalization; acquiring additional Common Stock and/or other equity, debt, notes, instruments or other securities of the Issuer (collectively, "Securities") or disposing of some or all of the Securities beneficially owned by them, in public market or privately negotiated transactions; entering into financial instruments or other agreements that increase or decrease the Reporting Person' economic exposure with respect to their investment in the Issuer; and/or otherwise changing their intention with respect to any and all matters referred to in Item 4 of Schedule 13D. | 2026-09-17 |
| QVCG | QVC GROUP, INC. | 3 | Stock Purchase Agreement On September 8, 2026, the Investment Manager, on behalf of the Funds, entered into a stock purchase agreement (the "Stock Purchase Agreement") with Silver Point Capital, L.P., pursuant to which the Funds agreed to purchase 1,600,000 shares of Common Stock for a purchase price of $16.25 per share (the "Purchase"). The Purchase closed on September 8, 2026. The foregoing description of the Stock Purchase Agreement does not purport to be complete and is qualified in its entirety by the full text of such agreement, which is attached as an exhibit to this Schedule 13D and incorporated herein by reference | 2026-09-10 |
| TACT | TRANSACT TECHNOLOGIES INC | 3 | The purpose of the acquisition of the Common Stock is for investment, and the acquisitions of the Common Stock were made in the ordinary course of business and were not made for the purpose of acquiring control of the Issuer. Although no Reporting Person has any specific plan or proposal to acquire or dispose of the Common Stock, consistent with its investment purpose, each Reporting Person at any time and from time to time may acquire additional Common Stock or dispose of any or all of its Common Stock depending upon an ongoing evaluation of the investment in the Common Stock, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Persons, and/or other investment considerations. Also, consistent with the investment purpose, the Reporting Person (Mr. Gillman) may engage in communications with one or more shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the board of directors of the Issuer and/or one or more representatives of the Issuer regarding the Issuer, including but not limited to its operations. The Reporting Person may discuss ideas that, if effected, may result in any of the following: the acquisition by persons of additional Common Stock of the Issuer, an extraordinary corporate transaction involving the Issuer, and/or changes in the board of directors or management of the Issuer. Mr. Gillman believes that the company is facing unique and very complicated challenges in its BOHA business. Mr. Gillman believes that these challenges require an immediate and urgent review of the BOHA business, including an exploration of strategic alternatives. To this end, Mr. Gillman believes that it is important for the board to add multiple new directors with the skills and experience to carry out this exploration of strategic alternatives for BOHA. Mr. Gillman believes that shareholders who share these concerns should communicate their concerns directly to each member of the incumbent board of directors. Mr. Gillman believes that the by laws of the company allow shareholders holding a majority of the voting rights to call a special meeting. Mr. Gillman believes that every single shareholder should today consider whether it is advisable at this time to call a special meeting of shareholders for the purpose of electing additional members to the board. At this time, Mr. Gillman has no specific plan or proposal to acquire or dispose of his Common Stock. Mr. Gillman may from time to time acquire additional Common Stock or dispose of any or all of his Common Stock depending upon an ongoing evaluation of the investment in the Common Stock, prevailing market conditions, other investment opportunities, liquidity requirements and/or other investment considerations. Also, consistent with the investment purpose, he may engage in communications with one or more shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the board of directors of the Issuer and/or one or more representatives of the Issuer regarding the Issuer, including but not limited to its operations. Mr. Gillman may discuss ideas that, if effected, may result in any of the following: the acquisition by persons of additional Common Stock of the Issuer, an extraordinary corporate transaction involving the Issuer, and/or changes in the board of directors or management of the Issuer. Except to the extent the foregoing may be deemed a plan or proposal, he has no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. Mr. Gillman may review or reconsider his position at any time. Mr. Gillman may change his goals with respect to TransAct at any time. Except to the extent the foregoing may be deemed a plan or proposal, Mr. Gillman has no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. Mr. Gillman may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto. Mr. Gillman believes that Daniel Friedberg effectively owns more stock in TransAct Technologies than any other board member. For this reason Mr. Gillman believes that Mr. Friedberg should be made board chairman and calls on the board to make this change immediately. | 2026-09-11 |
| RENT | Rent the Runway, Inc. | 3 | Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 6 of this Schedule 13D is incorporated by reference into this Item 4. | 2026-09-11 |
| EVGN | Evogene Ltd. | 3 | Item 4 of the Schedule 13D is hereby amended to add the following at the end thereof: On September 8, 2026, the Reporting Persons delivered a letter to the Issuer notifying the Issuer that they, acting individually or jointly, intend to commence a special tender offer pursuant to Section 328 of the Israeli Companies Law, 5759-1999, which, if consummated, would result in the Reporting Persons holding, in the aggregate, not less than 25% of the Issuer's outstanding voting rights. A copy of the letter is attached hereto as Exhibit 9 and is incorporated herein by reference. | 2026-09-11 |
| ADXN | Addex Therapeutics Ltd. | 2 | The Reporting Person acquired the securities of the Issuer at founding, through the exercise of options, acquisitions through participation in private placements and in consideration for his services as Chief Executive Officer of the Issuer. The reporting person also received shares issuable upon exercise of options. The terms of the Reporting Person's employment arrangements for 2025 were set forth in the Issuer's Annual Report on Form 20-F for such period filed by the Issuer with the Securities and Exchange Commission on May 15, 2026. Except in respect of such employment arrangements as set forth therein, the Reporting Person does not have any present plans which relate to or would result in: However, the Reporting Person reserves the right to change its plans at any time, as it deems appropriate, in light of its ongoing evaluation of (i) its business and liquidity objectives? (ii) the Issuer's financial condition, business, operations, competitive position, prospects and/or Share price? (iii) industry, economic and/or securities markets conditions? (iv) alternative investment opportunities? and (v) other relevant factors. | 2026-09-04 |
| CNXU | Conexeu Sciences Inc. | 2 | The information set forth in Items 3, 5 and 6 of this Schedule 13D is incorporated by reference herein. Background On May 14, 2025, the Issuer and 1036030 B.C. Ltd., a company solely owned by the Reporting Person, entered into a consulting services agreement pursuant to which the Reporting Person was granted 2,000,000 Performance Warrants to acquire shares of Common Stock at an exercise price of $0.001 per share, with a term of five years. The Performance Warrants vest contingent upon the occurrence of the following four specified performance milestones: - Milestone 1: 500,000 Performance Warrants shall vest upon the Issuer completing and receiving the results of a three-month collagen study conducted in Boston, Massachusetts; - Milestone 2: 500,000 Performance Warrants shall vest upon the Issuer listing its shares of Common Stock on the Nasdaq Stock Market, LLC, or any other recognized stock exchange in North America; - Milestone 3: 500,000 Performance Warrants shall vest upon the Issuer's listed shares of Common Stock trading for at least 20 consecutive trading days at a market capitalization of $80,000,000 or greater on a recognized North American stock exchange on which the shares of Common Stock are listed; and - Milestone 4: 500,000 Performance Warrants shall vest upon the Issuer's submission of a 510(k) application to the U.S. Food and Drug Administration. On July 8, 2025, Milestone 1 was achieved upon the Issuer completing and receiving the results of the three-month collagen study, resulting in the vesting of 500,000 Performance Warrants with respect to Milestone 1. On December 23, 2025, the Reporting Person exercised the vested 500,000 Performance Warrants in full, acquiring 500,000 shares of Common Stock at an exercise price of $0.001 per share, for aggregate consideration of $500.00 funded from the Reporting Person's personal funds. On May 21, 2026, the date of the Issuer's listing on the Nasdaq, 500,000 Performance Warrants held by the Reporting Person vested upon the occurrence of the listing milestone. On May 22, 2026, the Reporting Person exercised 500,000 Performance Warrants at an exercise price of $0.001 per share, for aggregate proceeds to the Issuer of $500.00, resulting in the issuance of 500,000 shares of Common Stock to the Reporting Person. On June 18, 2026, an additional 500,000 Performance Warrants held by the Reporting Person vested upon the Issuer's achievement of a market capitalization of $80,000,000 or greater for at least 20 consecutive trading days on the Nasdaq. On September 14, 2026, the Reporting Person exercised 500,000 Performance Warrants at an exercise price of $0.001 per share, for aggregate proceeds to the Issuer of $500.00, resulting in the issuance of 500,000 shares of Common Stock to the Reporting Person. This Amendment No.1 to the Schedule 13D is being filed to report the Reporting Person's updated beneficial ownership following the exercise of the June 2026 Vested Warrants on September 14, 2026. Purpose The Reporting Person acquired the securities described herein in connection with his compensation arrangements with the Issuer. The Reporting Person currently holds the shares of Common Stock and the Performance Warrants for investment purposes. The Reporting Person reserves the right to formulate other plans or make other proposals and take other actions with respect to his interest in the Issuer. Depending on market conditions and other factors, the Reporting Person may acquire or dispose of securities of the Issuer as the Reporting Person may deem appropriate, whether in open market purchases or sales, privately negotiated transactions or otherwise. The Reporting Person continues to evaluate numerous potential transactions and in connection therewith may exchange shares of Common Stock for other assets or may sell shares of Common Stock to increase his cash position. The Reporting Person may also reconsider and change his plans or proposals relating to the foregoing. Except as otherwise disclosed herein, the Reporting Person has no current plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. | 2026-09-15 |
| VRME | VerifyMe, Inc. | 2 | The 8% Convertible Subordinated Promissory Note in the principal amount of $175,000 (the Note), which was purchased by the Trust in the Issuer's private placement on August 25, 2023, matured on August 25, 2026. On August 25, 2026, the Issuer paid the Trust the principal amount of $175,000 plus accrued interest of $7,000, in accordance with the terms of the Note. Therefore, the Reporting Persons no longer beneficially own the 152,174 Shares into which the Note may have been converted. This has resulted in a change of 1% of the Reporting Person's beneficial ownership that was reported in the Schedule 13D (Amendment No. 2). | 2026-08-26 |
| TRMD | TORM plc | 2 | Item 4 of the Schedule 13D is hereby amended to incorporate the following at the end thereof: On September 14, 2026, Njord Luxco entered into an underwriting agreement dated September 14, 2026 (the "September 2026 Underwriting Agreement") by and among Njord Luxco, the Issuer, and J.P. Morgan Securities LLC (the "Underwriter") for the sale by Njord Luxco of 9,000,000 Class A Shares (the "Initial Shares") to the Underwriter at a price of $31.75 per share, or $285,750,000.00 in aggregate proceeds to Njord Luxco before expenses (the "September 2026 Block Trade"). The closing of the sale of the Initial Shares by Njord Luxco to the Underwriter pursuant to the Underwriting Agreement occurred on September 16, 2026. In addition, pursuant to the Underwriting Agreement, Njord Luxco granted the Underwriter an option for a period of 30 days to purchase up to 1,350,000 additional Class A Shares (the "Option Shares") at the same price per share as the Initial Shares. In connection with the execution of the Underwriting Agreement for the September 2026 Block Trade, Njord Luxco and certain other persons entered into customary "lock-up" agreements with the Underwriter, dated September 14, 2026 (the "September 2026 Lock-up Agreements"), pursuant to which Njord Luxco and certain other persons generally agreed, subject to certain exceptions, not to sell, transfer, or otherwise dispose of any Class A Shares or securities convertible into, or exchangeable or exercisable for, Class A Shares, during the period commencing on September 14, 2026 and ending on November 13, 2026, without prior written consent from the Underwriter. The foregoing descriptions of the September 2026 Underwriting Agreement and the September 2026 Lock-up Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the September 2026 Underwriting Agreement, a copy of which is attached hereto as Exhibit A, and the form of the September 2026 Lock-up Agreement attached as Exhibit E to the September 2026 Underwriting Agreement, both of which are incorporated by reference herein. | 2026-09-17 |
| BHR | Braemar Hotels & Resorts Inc. | 2 | Item 4 is hereby amended to add the following: On September 8, 2026, the Reporting Persons issued a press release regarding an open letter (the "September 8, 2026 Letter") to the Issuer's shareholders. In the September 8, 2026 Letter, the Reporting Persons reiterated their intent to nominate a slate of qualified and independent director nominees for election to the Issuer's Board at the 2026 Annual Meeting. The foregoing summary of the September 8, 2026 Letter does not purport to be complete and is subject to, and qualified in its entirety by, the September 8, 2026 Letter, a copy of which is attached here as Exhibit 12 and incorporated herein by reference. | 2026-09-15 |
| RCT | RedCloud Holdings plc | 2 | Reporting Person has no current plans relating to (a) through (j) of Item 4. The Reporting Person may, at any time and from time to time, review or reconsider her position and/or change her purpose. | 2026-09-02 |
| JCSE | JE Cleantech Holdings Limited | 2 | The Reporting Persons hold the Class B Ordinary Shares of the Issuer for investment purposes. | 2026-09-16 |
| BNBX | BNB PLUS CORP. | 2 | Item 4 of the Schedule 13D is hereby amended to add the following: Strategic Review Update; Relationship to GlobalStake. The strategic review of the Issuer's businesses being conducted by an affiliate of the Reporting Persons has been substantially undertaken, and the Board has considered and, in certain cases, begun to implement recommendations arising from that review. Specifically, an existing asset management agreement has been terminated, resulting in significant net savings for the Issuer. In addition, the review suggested the addition to the Board of members with digital asset and related industry experience. Richard Shorten indirectly controls GlobalStake, the entity engaged by the Issuer to conduct the strategic review, and serves as the engagement leader for GlobalStake's engagement by the Issuer. The Reporting Persons expect that additional recommendations arising from the strategic review may be considered and, if approved by the Board, implemented in the future. Certain recommendations arising from the strategic review may involve transactions in which GlobalStake or its affiliates would be a principal party. Appointment of Richard Shorten to the Board. Richard Shorten, a Reporting Person, was appointed to serve as a member (and new Chairman) of the Board, effective September 3, 2026. Prior to such appointment, Richard Shorten was interviewed by the Issuer's nominating committee and by the Board. Following that process, the committee recommended, and the Board independently determined, to appoint Richard Shorten to the Board. Recommendation of Additional Director Candidates; Resulting Board Composition. In connection with the Board's consideration of candidates, the Reporting Persons recommended two individuals, Lok Lee and Todd Larsen, as potential director candidates. The Issuer's nominating committee and the Board interviewed each candidate, independently evaluated his qualifications, and thereafter independently determined to appoint each such individual to the Board, effective September 3, 2026. As of the date of this Amendment, the Board consists of five members, of whom three - Richard Shorten, Todd Larsen and Lok Lee - were appointed following the Reporting Persons' recommendation. The Reporting Persons do not have any agreement, arrangement, or understanding - written or oral, formal or informal - with any candidate appointed or nominated to the Board regarding such person's service on the Board, the exercise of such person's fiduciary duties, or the acquisition, holding, voting, or disposition of any securities of the Issuer. Conflicts Process. The Reporting Persons have advised the Issuer that Richard Shorten will recuse himself from Board deliberations and voting with respect to the engagement of GlobalStake and with respect to any transaction in which GlobalStake may have an interest or otherwise as may be required by applicable law. No Agreements Regarding Board Service or Securities. The Reporting Persons have no agreement, arrangement, or understanding with the Issuer with respect to the appointment of Richard Shorten or of any other individual to the Board, and have no right to designate any director of the Issuer. The Reporting Persons have no agreement, arrangement, or understanding of any kind with the individuals recommended as director candidates, with respect to (i) the acquisition, holding, voting, or disposition of any securities of the Issuer, (ii) such individuals' service on, or conduct as members of, the Board, or (iii) the exercise of such individuals' fiduciary duties. Neither of such individuals is employed by, or receives any compensation, indemnification, or reimbursement from, the Reporting Persons or any of their affiliates with respect to service on the Board and, to the knowledge of the Reporting Persons, neither such individual owns any securities of the Issuer. Disclaimer of Group Status. The Reporting Persons expressly disclaim membership in any 'group' within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5(b) thereunder, with (i) the Issuer, (ii) any other stockholder of the Issuer, or (iii) any member of the Board, including any director recommended by the Reporting Persons. Each member of the Board exercises independent judgment and owes fiduciary duties to the Issuer and all of its stockholders. Continuing Reservation of Rights. The Reporting Persons intend to continue to engage with the Issuer's Board and management regarding the strategic direction of the Issuer, the implementation of recommendations arising from the strategic review, and other matters affecting shareholder value. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may, at any time and from time to time, engage in discussions with members of the Board, management of the Issuer, other stockholders, potential investors, strategic partners and other interested parties regarding the Issuer's business, operations, management, governance, strategy, capitalization, capital allocation, financial condition and prospects. Depending upon various factors, including the Issuer's business and financial position and prospects, the price level of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may, at any time and from time to time, review or reconsider their position, change their purpose, formulate plans or proposals with respect thereto, or take any other action with respect to their investment in the Issuer as they deem appropriate, including acquiring additional securities, disposing of securities, proposing or considering changes in the Issuer's operations, management, Board composition, governance, capitalization or strategic direction, or considering or proposing one or more of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. | 2026-09-04 |
| HGTY | Hagerty, Inc. | 2 | The responses to Item 3 and Item 6 of this Schedule 13D are incorporated by reference herein. Hagerty Holding Corp., a Delaware close corporation ("HHC") acquired the shares of Class V common stock, par value $0.0001 per share ("Class V Common Stock"), of Hagerty, Inc. (the "issuer" or the "Company") for investment purposes. HHC expects to review from time to time its investment in the Company and, depending on its applicable legal, regulatory and contractual obligations (including as described in Item 6 herein), the Company's financial position, business prospects and investment strategy, and prevailing market, economic and industry conditions, HHC may in the future take such actions with respect to its investment in the Company as it deems appropriate, including, among other things: (i) purchasing shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the Company, and other securities of the Company in the open market, in privately negotiated transactions or otherwise; (ii) surrendering shares of Class V Common Stock and limited liability company interests ("OpCo Units") of The Hagerty Group, LLC ("OpCo") in exchange for shares of Class A Common Stock or, at the option of the Company, cash, including, without limitation, as described in the following paragraph; or (iii) changing its intention with respect to any and all matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. During each annual period commencing on the third anniversary of December 2, 2021, any of McKeel Hagerty, Tammy Hagerty or the Kim Hagerty Revocable Trust may require HHC to surrender for exchange Class V Common Stock and OpCo Units for Class A Common Stock in an amount up to 2% of the fully-diluted outstanding shares of Class A Common Stock and to use the net proceeds of such exchange to redeem a corresponding portion of HHCshares; provided, that, in no event will HHC be required to surrender such interests for exchange if, prior to the 15th anniversary of December 2, 2021, as a result of the exchange, HHC would cease to hold at least 55% of the voting power of the Company. Also, in the event that either of McKeel Hagerty or Tammy Hagerty dies, the estate of the deceased stockholder of HHC may cause HHC to surrender for exchange Class V Common Stock and OpCo Units in an amount necessary to cover the estate obligations of the deceased stockholder's estate after taking into account certain other resources available to the estate, including the amount of any life insurance proceeds received by the estate. Underwriting Agreement. On September 9, 2026, the Company, OpCo and HHC entered in an underwriting agreement (the "Underwriting Agreement") with Wells Fargo Securities, LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters listed in Schedule 1 thereto (collectively, the "Underwriters"), pursuant to which HHC sold 10,637,500 shares of Class A Common Stock at a public offering price of $11.95 per share (the "Offering"). The Offering was made pursuant to the Company's effective registration statement, previously filed with the Securities and Exchange Commission. The Underwriting Agreement contains customary representations, warranties and agreements of the parties, conditions to closing, and indemnification obligations of the parties. The foregoing is a summary description of the Underwriting Agreement and is qualified in its entirety by the text of the Underwriting Agreement attached as Exhibit 1.1 to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 11, 2026, and incorporated herein by reference. Lock-Up Agreement. In connection with the Offering, HHC also entered into a customary lock-up agreement with the representatives of the Underwriters pursuant to which HHC has agreed that, for a period of 60 days after September 9, 2026, it will not, without the prior written consent of the representatives on behalf of the Underwriters, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of the Company's capital stock or any securities convertible into or exercisable or exchangeable for the Company's capital stock (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the such securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of such securities, in cash or otherwise, (3) make any demand for, or exercise any right with respect to, the registration of any such securities, or (4) publicly disclose the intention to do any of the foregoing. The restrictions described in the immediately preceding paragraph do not apply to: (a) transfers of securities: (i) as bona fide gifts, or for bona fide estate planning purposes, (ii) by will or intestacy, (iii) to any trust for the direct or indirect benefit of HHC or any immediate family member, (iv) to a corporation, partnership, limited liability company or other entity of which HHC and its immediate family members are the legal and beneficial owner of all of the outstanding equity securities or similar interests, (v) by operation of law, (vi) to the Company from an employee upon death, disability or termination of employment of such employee, (vii) as part of a sale of such securities acquired in open market transactions after the completion of the Offering, among other transactions, or (viii) to the Company in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of Class A Common Stock, in each case provided that the party acquiring the securities agrees to the same restrictions and subject to certain notice requirements and publicity limitations; (b) the exercise of outstanding options, settlement of restricted stock units or other equity awards, or the exercise of warrants described in this prospectus, provided that the securities received upon such exercise or settlement would be subject to these restrictions; (c) the conversion or exchange of outstanding Class V Common Stock, preferred stock, warrants or other securities ultimately convertible into or exchangeable for shares of Class A Common Stock, provided that any Class A Common Stock received upon such conversion or exchange would be subject to these restrictions; (d) the establishment by HHC of trading plans under Rule 10b5-1 under the Act, provided that such plan does not provide for the transfer of securities during the 60-day restricted period; and (e) the sale of Class A Common Stock pursuant to the terms of the Underwriting Agreement. Except as set forth above, HHC currently has no plans or proposals that relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. HHC may, at any time and from time to time, review or reconsider its position and/or change its purpose and/or formulate plans or proposals with respect thereto. | 2026-09-14 |
| HEPS | D-MARKET Electronic Services & Trading | 2 | The disclosure in Item 4 of the Schedule 13D, as amended, is hereby supplemented by adding the following: The information set forth in Item 3 of this Amendment No. 9 is incorporated by reference into this Item 4. The disclosure in Item 4 of the Schedule 13D, as amended, is hereby amended by replacing the last paragraph of that item with the following: The Reporting Person is the controlling shareholder of the Issuer. As of the date of this filing, Mikheil Lomtadze, Yuri Didenko, Sandro Berdzenishvili, Pavel Mironov and Tengiz Mosidze, each of which are employees of the Reporting Person, serve as directors of the Issuer. In their capacity as directors of the Issuer, such individuals take an active role in working with the Issuer's management on operational, financial and strategic initiatives. Other than as described above or in Item 6, the Reporting Person has no present plan or proposal which relates to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although the Reporting Person expects to evaluate the Issuer's financial condition and prospects and its interest in the Issuer on an ongoing basis. Accordingly, the Reporting Person reserves the right to change its plans and intentions at any time, as it deems appropriate based on any such evaluation. The Reporting Person reviews its investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position, results and strategic direction, price levels of the Issuer's securities, the Issuer's response to the matters to be discussed with the Reporting Person, actions taken by management and the Board, the Reporting Person's overall investment strategies, liquidity requirements, other investment opportunities available to the Reporting Person, applicable legal and regulatory constraints, conditions in the securities and capital markets, and general economic and industry conditions, the Reporting Person may, from time to time and at any time, in the future purchase additional securities of the Issuer or dispose of some or all of their securities of the Issuer, in the open market, in private transactions or otherwise, or enter into financial instruments or other agreements that increase or decrease the Reporting Person's economic exposure with respect to their investment in the Issuer, which may or may not affect their beneficial ownership in securities of the Issuer. In addition, the Reporting Person may, at any time and from time to time, propose or consider one or more actions with respect to its investment in the Issuer as it deems appropriate, that relate to or could result in any or all of the matters described or referred to in subparagraphs (a)-(j) of Item 4 of Schedule 13D. The Reporting Person may also engage in discussions with management, other stockholders of the Issuer and other relevant parties concerning the business, operations, management, strategy and future plans of the Issuer, and may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements, or take steps to explore and prepare for various plans and actions before forming an intention to engage in such plans or actions. The foregoing list of intentions, plans, strategies, negotiations, discussions, activities and potential transactions under consideration is subject to termination, evolution, modification or change at any time, without notice, and there can be no assurance that the Reporting Person will take any of the actions set forth above. | 2026-09-15 |
| APGE | APOGEE THERAPEUTICS, INC. | 2 | Item 4 of the Statement is hereby amended and supplemented as follows: On June 18, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with AbbVie Inc. ("AbbVie"), Andor LLC, a wholly owned subsidiary of AbbVie ("Parent"), and Andor Merger Co., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on September 3, 2026, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"): (i) each share of voting common stock of the Issuer, par value $0.00001 per share, and each share of non-voting common stock of the Issuer, par value $0.00001 per share (each, a "Share"), outstanding immediately prior to the Effective Time, but excluding each Share (A) owned by the Issuer or any of its wholly owned subsidiaries, (B) held by AbbVie, Parent, Merger Sub or any other wholly owned subsidiary of AbbVie, and (C) held by a stockholder who had not voted in favor of the adoption of the Merger Agreement or consented thereto and who was entitled to and properly demanded appraisal, was cancelled and converted into the right to receive $135.11 per Share in cash (the "Merger Consideration"), without interest and subject to any applicable tax withholding; (ii) each option to purchase Shares (each, an "Issuer Option") outstanding immediately prior to the Effective Time (whether vested or unvested) that had an exercise price per Share less than the Merger Consideration was cancelled and converted into the right to receive cash in an amount equal to the product of: (A) the total number of Shares subject to such Issuer Option immediately prior to the Effective Time, multiplied by (B) the excess of (x) the Merger Consideration over (y) the exercise price per Share under such Issuer Option, without interest and subject to any applicable tax withholding. Each Issuer Option outstanding immediately prior to the Effective Time (whether vested or unvested) that had an exercise price per Share greater than or equal to the Merger Consideration was cancelled without any consideration being payable in respect thereof, and had no further force or effect; (iii) each restricted stock unit award of the Issuer (each, a "Issuer RSU") outstanding immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive a lump sum cash payment, without interest and subject to any applicable tax withholding, equal to the product of (A) the Merger Consideration, multiplied by (B) the number of Shares subject to such Issuer RSU; (iv) each outstanding restricted stock award of the Issuer (the "Issuer Restricted Stock") outstanding immediately prior to the Effective Time became fully vested and was converted into the right to receive the Merger Consideration for each such share of Issuer Restricted Stock; and (v) each warrant exercisable for Shares (each, a "Issuer Warrant") outstanding immediately prior to the Effective Time, in accordance with its terms, became exercisable by the holder thereof solely for the same Merger Consideration that such holder would have been entitled to receive if such holder had been, immediately prior to the Effective Time, the holder of the number of Shares that were issuable upon exercise in full of such Issuer Warrant without regard to any limitations on exercise contained in such Issuer Warrant. Pursuant to the Merger, the Reporting Persons disposed of an aggregate of 1,750,000 shares of voting common stock, 6,743,321 shares of non-voting common stock, 365,853 pre-funded warrants and stock options exercisable for an aggregate of 80,246 shares for the consideration described above. As a result of the Merger, the common stock ceased to trade on the Nasdaq Global Market prior to the opening of trading on September 4, 2026 and became eligible for delisting from the Nasdaq Global Market and termination of registration pursuant to Rules 12g-4(a)(1) and 12h-3(b)(1)(i) of the Act. | 2026-09-08 |
| XBP | XBP Global Holdings, Inc. | 2 | Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following thereto: The Private Placement On September 11, 2026, the Issuer entered into securities purchase agreements (each, a "Purchase Agreement") with certain accredited investors (the "Purchasers"), for the sale by the Issuer in a private placement (the "Private Placement") of an aggregate of 2,275,245 shares (the "Shares") of the Issuer's Common Stock, at a weighted purchase price of approximately $2.66 per Share, for aggregate gross proceeds to the Issuer of approximately $6.05 million. Avenue RP Opportunities Fund, L.P., Avenue Global Dislocation Opportunities Fund, L.P. and Avenue Global Opportunities Master Fund LP, each a fund managed by investment advisers affiliated with Avenue Capital Group ("Avenue") participated as a Purchaser in the Private Placement, purchasing 600,000 shares of Common Stock in the aggregate. Mr. Randal Klein, a member of the Board, is a portfolio manager at Avenue. All purchases made by Avenue were made at a per share price of $2.83, which is the consolidated closing bid price of the Common Stock immediately preceding entry into the Private Placement, and the remainder of the Shares were purchased at a per share price of $2.55. The closing of the Private Placement occurred on September 15, 2026. The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by the full text of the Purchase Agreement, a copy of which is included as Exhibit 99.4 to this Amendment, and is incorporated by reference herein. On September 11, 2026, in connection with the Purchase Agreement, the Issuer entered into Registration Rights Agreements with the Purchasers (each, a "Registration Rights Agreement"). The Registration Rights Agreement provides, among other things, that the Issuer will file with the SEC a registration statement registering the resale of the Shares no later than September 22, 2026. The Issuer agreed to use commercially reasonable efforts to have such registration statement declared effective as soon as practicable after the filing thereof. The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by the full text of the Registration Rights Agreement, a copy of which is included as Exhibit 99.5 to this Amendment, and is incorporated by reference herein. | 2026-09-17 |
| GETY | Getty Images Holdings, Inc. | 2 | Item 4 of the Existing Statement is hereby amended and supplemented as follows: On July 21, 2026, the Issuer publicly disclosed that it was evaluating strategic financing alternatives and balance sheet management initiatives related to its capital structure, liquidity position, and financial outlook, and had engaged Guggenheim Securities, LLC as its financial advisor in connection therewith. In connection with the foregoing, the Reporting Persons have from time to time engaged in, and intend to continue to engage in, discussions regarding the Issuer's strategic and liquidity alternatives and potential capital solutions available to the Issuer with the Issuer and with other current or prospective holders of the Issuer's debt securities or other indebtedness, sources of credit and other third parties. In connection with such discussions, effective as of August 25, 2026, the Reporting Persons and KED acknowledged the formation of a "group" within the meaning of Section 13(d)(3) of the Act (KED and the Reporting Persons, collectively, the "Proposed Transaction Group") with respect to any such alternatives and potentially providing capital solutions (subject to agreements with certain stakeholders). Accordingly, activities discussed in this Item 4 may be undertaken by the Proposed Transaction Group. Either the Reporting Persons or KED may cease to participate in the Proposed Transaction Group at any time upon notice to the other. The Reporting Persons are not, and do not intend to become, joint filers with KED, and the Joint Filing Agreement, dated September 6, 2022, a copy of which was filed with the Original Statement as an exhibit, remains in effect solely among the Reporting Persons. The Reporting Persons and KED are individually filing Schedule 13D filings pursuant to Rule 13d-1(k)(2) under the Act. Except with respect to the Proposed Transaction Group, nothing herein shall be construed as an admission that the Reporting Persons are, or have become, members of a "group" (within the meaning of Section 13(d)(3) of the Act). The Reporting Persons or their affiliates may participate in any transaction resulting from the Issuer's evaluation, and certain of the capital solutions under consideration, if pursued, could relate to or result in one or more of the actions or transactions described in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may consider and negotiate potential agreements with respect to or relating to, among other things, the foregoing matters. The Reporting Persons have not determined to pursue any particular course of action, and there can be no assurance that the Reporting Persons will pursue any capital solution or that any transaction will result. The Reporting Persons are under no obligation to pursue any capital solution and may discontinue their engagement in discussions at any time and for any reason. Nothing in this Item 4 constitutes an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may from time to time formulate plans or proposals, negotiate agreements with respect to such plans or proposals, and take such actions with respect to their investment as they deem appropriate, depending on various factors, including the Issuer's financial position and strategic direction, actions taken by the Issuer's board of directors, management or other stakeholders, conditions in the securities markets and general economic and industry conditions. The Reporting Persons undertake no obligation to make any additional disclosure, except to the extent required by law. | 2026-08-26 |
| EDSA | EDESA BIOTECH, INC. | 2 | Item 4 is hereby amended to add the following: On August 21, 2026, in an underwritten public offering (the "Offering"), Velan Master purchased 445,100 Shares and certain warrants (the "New Warrants") exercisable into 445,100 Shares and Velan Horizon purchased 9,445 Shares and New Warrants exercisable into 9,445 Shares. Velan Master and Velan Horizon may not exercise any portion of the New Warrants to the extent that they would beneficially own more than 9.99% of the number of Shares outstanding immediately after giving effect to such exercise. However, upon at least 61 days' prior notice to the Issuer, such Reporting Person may increase or decrease such beneficial ownership limitation, as applicable, but not to any percentage in excess of 9.99% (the "Warrant Ownership Limitation"). Each New Warrant is exercisable for one Share at an exercise price of $7.50 per Share. The New Warrants are exercisable at any time after their original issuance and may be exercised until the date that is the earlier of (i) the 18-month anniversary of the original issuance date and (ii) the 30th day following the date of the Issuer's public announcement of Phase 2 vitiligo topline data for EB06. The exercise price and the number of Shares issuable upon exercise of the New Warrants are subject to appropriate adjustment in the event of certain share dividends, share splits, share combinations or other similar reclassifications affecting the Shares. The foregoing description of the New Warrant is qualified in its entirety by reference to the full text of the New Warrant, which is included as Exhibit 99.1 hereto and is incorporated by reference herein. | 2026-08-25 |
| EAF | GRAFTECH INTERNATIONAL LTD | 2 | Item 4 is hereby amended to add the following: The Reporting Persons acquired the additional Shares reported in this Amendment for investment purposes, based on their belief that the Common Stock is an attractive investment in light of current industry conditions. The Reporting Persons may acquire additional shares of Common Stock from time to time in open market transactions, privately negotiated transactions or otherwise, or may dispose of shares of Common Stock, in each case depending upon market conditions, the price and availability of the Common Stock, and other investment considerations, and in each case subject to the terms of the Cooperation Agreement described in the Schedule 13D. | 2026-09-18 |
| SRL | Scully Royalty Ltd. | 2 | Item 4 of the Schedule 13D is amended and supplemented as follows: On September 14, 2026, certain members of the Reporting Group delivered a Notice of Requisition for Extraordinary General Meeting (the "Requisition Notice") to the Issuer pursuant to Article 16.3 of the Amended and Restated Articles of Association of the Company adopted by special resolution dated July 12, 2017 (the "Articles"). Pursuant to the Articles and the Requisition Notice, the Issuer is required to proceed to convene an extraordinary general meeting of the members of the Issuer ("EGM") for the purposes of considering, and if thought fit, passing ordinary resolutions appointing each of Jerrod Freund, Mark Holliday, Nimesh Patel and Skyler Wichers (the "Director Nominees") as a Director of the Issuer, succeeding Michael J. Smith, Dr. Shuming Zhao, Silke S. Stenger and Jochen Dumler (the "Incumbent Directors"), respectively, and, in the event that such ordinary resolutions are later determined for any reason to be ineffective, members of the Issuer are also asked to vote on special resolutions removing each of the Incumbent Directors and any Director of the Issuer appointed by the Incumbent Directors between the date of the Requisition Notice and the conclusion of the EGM and ordinary resolutions appointing each of the Director Nominees. | 2026-09-16 |
| ティッカー | 報告者 | 種類 | 報告日 | 保有株数 | 保有比率 | |
|---|---|---|---|---|---|---|
| AMG BBH Asset-Backed Credit Fund, LLC | BROWN BROTHERS HARRIMAN & CO | 13D/A | 2026-09-18 | 3.02M | 66.2% | |
| FRHC | Turlov Timur R | 13D/A | 2026-09-18 | 41.41M | 64.9% | |
| ATNI | Cornelius B. Prior, Jr. | 13D/A | 2026-09-18 | 4.34M | 28.2% | |
| KKR Real Estate Select Trust Inc. | KKR Alternative Assets LLC | 13D/A | 2026-09-18 | 9.87M | 29.4% | |
| EL | Trust Under Article 2 of The Zinterhofer 2008 Descendants Trust Agreement | 13D/A | 2026-09-18 | 4.91M | 1.9% | |
| MLCO | Melco International Development Limited | 13D/A | 2026-09-18 | 687.36M | 56.3% | |
| MG | Mill Road Capital III, L.P. | 13D/A | 2026-09-18 | 1.94M | 6.1% | |
| OSCR | Thrive Capital Partners II, L.P. | 13D/A | 2026-09-18 | 37.53M | 12.1% | |
| Direxion Shares ETF Trust | Upender V. Rao | 13G/A | 2026-09-18 | 100K | 11.0% | |
| BZAI | Lane Bess | 13D/A | 2026-09-18 | 13.02M | 9.0% | |
| JATT | JATT Ventures II L.P. | 13D/A | 2026-09-18 | 1.80M | 23.1% | |
| MRDN | Anthony Brian Goodman | 13D/A | 2026-09-18 | 698K | 5.5% | |
| ELOG | Albert Wong | 13D/A | 2026-09-18 | 5.55M | 39.8% | |
| MRLN | FR Capital Holdings, L.P. | 13G/A | 2026-09-18 | 1.03M | 1.0% | |
| NUWE | Orca Capital AG | 13G/A | 2026-09-18 | 181K | 4.9% | |
| BRR | Anthony Pompliano | 13D/A | 2026-09-18 | 14.65M | 17.4% | |
| BTMD | AGARWAL AMIT MOHAN | 13G/A | 2026-09-18 | 2.40M | 8.4% | |
| EAF | Undavia Nilesh | 13D/A | 2026-09-18 | 2.21M | 8.5% | |
| PCQ | BANK OF AMERICA CORP /DE/ | 13D/A | 2026-09-17 | 2K | 79.4% | |
| EVF | MORGAN STANLEY | 13G/A | 2026-09-17 | 0 | 0.0% | |
| MEOH | Key Group Long Term Investments LP | 13G/A | 2026-09-17 | 5.34M | 6.9% | |
| MEOH | Key Group Long Term Investments LP | 13G/A | 2026-09-17 | 6.43M | 8.3% | |
| RGR | Beretta Holding S.A. | 13D/A | 2026-09-17 | 1.59M | 9.9% | |
| SHAZ | Situational Awareness LP | 13D/A | 2026-09-17 | 8.07M | 21.1% | |
| SGHC | Chivers Limited | 13D/A | 2026-09-17 | 90.17M | 17.7% | |
| GTE | Equinox Partners Investment Management LLC | 13G/A | 2026-09-17 | 1.53M | 4.3% | |
| SWMR | Philip Wagenheim | 13D/A | 2026-09-17 | 0 | 0.0% | |
| XBP | Exela Technologies, Inc. | 13D/A | 2026-09-17 | 3.84M | 25.9% | |
| XBP | Avenue RP Opportunities Fund, L.P. | 13D/A | 2026-09-17 | 1.81M | 12.8% | |
| TRMD | Hafnia Limited | 13D/A | 2026-09-17 | 18.66M | 18.2% | |
| FANG | SGF FANG Holdings, LP | 13D/A | 2026-09-17 | 64.96M | 23.2% | |
| TALO | Carlos Slim Helu | 13D/A | 2026-09-17 | 39.08M | 23.4% | |
| CHR | Bing Zhang | 13D/A | 2026-09-17 | 13K | 0.7% | |
| TYRA | RA Capital Management, L.P. | 13D/A | 2026-09-17 | 14.13M | 19.9% | |
| AUR | Uber Technologies, Inc. | 13D/A | 2026-09-17 | 157.10M | 9.2% | |
| ARDC | THRIVENT FINANCIAL FOR LUTHERANS | 13G/A | 2026-09-16 | 800K | 20.0% | |
| NSLR | GAMCO INVESTORS, INC. ET AL | 13D/A | 2026-09-16 | 1.61M | 6.1% | |
| GNK | DIANA SHIPPING INC. | 13D/A | 2026-09-16 | 2.18M | 4.9% | |
| LODE | MAK Capital Fund LP | 13D/A | 2026-09-16 | 5.07M | 6.7% | |
| ONC | Baker Bros. Advisors LP | 13D/A | 2026-09-16 | 115.91M | 7.8% | |
| SRL | Peter R. Kellogg | 13D/A | 2026-09-16 | 5.40M | 35.5% | |
| TVGN | Kirti Desai | 13D/A | 2026-09-16 | 993K | 6.3% | |
| TVGN | Saadi Ryan H. | 13D/A | 2026-09-16 | 11.71M | 74.4% | |
| TRMD | OCM NJORD HOLDINGS S.A R.L. | 13D/A | 2026-09-16 | 11.33M | 11.1% | |
| NYAX | MEITAV INVESTMENT HOUSE LTD | 13G/A | 2026-09-16 | 1.83M | 5.0% | |
| SRL | Neil S. Subin | 13D/A | 2026-09-16 | 1.99M | 13.0% | |
| FTFT | Wealth Index Capital Limited | 13D/A | 2026-09-16 | 2.64M | 32.5% | |
| Prospect Enhanced Yield Fund | Eliasek M Grier | 13D/A | 2026-09-16 | 148K | 11.6% | |
| NEPH | Wexford Capital LP | 13D/A | 2026-09-16 | 224K | 2.1% | |
| HEPA | KI Holdings Ltd. | 13D/A | 2026-09-16 | 10.00M | 10.2% | |
| BRUN | Sean Goodrich | 13D/A | 2026-09-16 | 4.44M | 8.9% | |
| VNRX | Lagoda Investment Management, L.P. | 13D/A | 2026-09-16 | 1.65M | 5.9% | |
| JCSE | HONG Bee Yin | 13D/A | 2026-09-16 | 3.45M | 100.0% | |
| JCSE | HONG Bee Yin | 13D/A | 2026-09-16 | 325K | 15.0% | |
| SOBR | Corley Thomas John | 13G/A | 2026-09-16 | 835K | 15.5% | |
| INTR | SQUADRA INVESTMENTS - GESTAO DE RECURSOS LTDA. | 13G/A | 2026-09-15 | 16.06M | 4.9% | |
| DBI | Stone House Capital Management, LLC | 13D/A | 2026-09-15 | 7.00M | 16.1% | |
| GPUS | Ault & Company, Inc. | 13D/A | 2026-09-15 | 318.61M | 63.5% | |
| CNXU | Jeffrey Sharpe | 13D/A | 2026-09-15 | 1.50M | 5.2% | |
| PETV | A.L. Sarroff Fund, LLC | 13D/A | 2026-09-15 | 16.94M | 38.2% |